Summary
Cencora, Inc. (formerly AmerisourceBergen) reported significant revenue growth in its fiscal year ending September 30, 2019, with a 6.9% increase driven primarily by its Pharmaceutical Distribution Services segment. This growth was supported by strong specialty product sales, the consolidation of Profarma, and the acquisition of H.D. Smith. The company's diversification into Animal Health and Global Commercialization Services also contributed positively. Despite revenue increases, operating income saw a substantial decrease of 23.0% due to a significant $570 million impairment of long-lived assets related to its PharMEDium compounding operations, coupled with increased employee severance, litigation, and other costs. However, the company also benefited from gains on antitrust litigation settlements and a favorable LIFO credit compared to the prior year. Significant legal and operational challenges were noted, particularly concerning PharMEDium's regulatory compliance and the ongoing opioid litigation, which continue to be material factors impacting the company's financial performance and outlook.
Financial Highlights
56 data points| Revenue | $179.59B |
| Cost of Revenue | $174.45B |
| Gross Profit | $5.14B |
| SG&A Expenses | $2.66B |
| Operating Income | $1.11B |
| Net Income | $855.37M |
| EPS (Basic) | $4.07 |
| EPS (Diluted) | $4.04 |
| Shares Outstanding (Basic) | 210.16M |
| Shares Outstanding (Diluted) | 211.84M |
Key Highlights
- 1Revenue increased by 6.9% to $179.6 billion for the fiscal year ended September 30, 2019, driven by the Pharmaceutical Distribution Services segment.
- 2Operating income decreased by 23.0% to $1.1 billion, primarily due to a $570 million impairment of long-lived assets related to PharMEDium.
- 3The company reported net income attributable to AmerisourceBergen Corporation of $855.4 million, a significant decrease from $1.66 billion in the prior year, largely due to the asset impairment and a large tax benefit in the prior year.
- 4The company's two largest customers, Walgreens Boots Alliance and Express Scripts, accounted for approximately 34% and 13% of revenue, respectively.
- 5Significant legal matters, including ongoing opioid litigation and regulatory issues with its PharMEDium subsidiary, continue to represent material risks and potential costs.
- 6The company repurchased $664.8 million of its common stock under its share repurchase programs during the fiscal year.
- 7Gross profit increased by 11.4% due to higher distribution revenue, antitrust litigation gains, and a LIFO credit.